Sera Prognostics (NASDAQ:SERA) CEO Sells $40,278.00 in Stock

Sera Prognostics, Inc. (NASDAQ:SERA) CEO Zhenya Lindgardt sold 20,139 shares of Sera Prognostics stock in a transaction that occurred on Tuesday, September 8th. The shares were sold at an average price of $2.00, for a total transaction of $40,278.00. Following the transaction, the chief executive officer directly owned 844,870 shares in the company, valued at approximately $1,689,740. The trade was a 2.33% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Zhenya Lindgardt also recently made the following trade(s):

• On Thursday, September 10th, Zhenya Lindgardt sold 7,022 shares of Sera Prognostics stock. The stock was sold at an average price of $2.00, for a total value of $14,044.00.

Sera Prognostics Stock Down 1.0%

Sera Prognostics stock opened at $2.03 on Friday. The firm has a market cap of $80.08 million, a P/E ratio of -3.03 and a beta of 0.98. The business has a fifty day moving average of $2.05 and a two-hundred day moving average of $2.02. Sera Prognostics, Inc. has a twelve month low of $1.56 and a twelve month high of $3.95.

Sera Prognostics (NASDAQ:SERA) last announced its quarterly earnings results on Wednesday, August 12th. The company reported ($0.18) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.15) by ($0.03). Sera Prognostics had a negative net margin of 47,475.72% and a negative return on equity of 46.71%. The company had revenue of $0.03 million during the quarter, compared to analysts’ expectations of $0.07 million. Equities analysts expect that Sera Prognostics, Inc. will post -0.62 earnings per share for the current year.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the business. AWM Investment Company Inc. purchased a new stake in Sera Prognostics during the 2nd quarter valued at about $377,000. Captrust Financial Advisors increased its holdings in shares of Sera Prognostics by 20.0% in the second quarter. Captrust Financial Advisors now owns 602,277 shares of the company’s stock valued at $1,668,000 after purchasing an additional 100,366 shares during the period. Segall Bryant & Hamill LLC purchased a new position in shares of Sera Prognostics in the first quarter worth about $193,000. Jane Street Group LLC purchased a new position in shares of Sera Prognostics in the fourth quarter worth about $203,000. Finally, Vanguard Group Inc. lifted its holdings in shares of Sera Prognostics by 4.6% during the third quarter. Vanguard Group Inc. now owns 1,217,190 shares of the company’s stock worth $3,725,000 after purchasing an additional 54,008 shares during the period. 54.64% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of analysts have recently weighed in on the stock. Weiss Ratings upgraded shares of Sera Prognostics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday. Craig Hallum began coverage on shares of Sera Prognostics in a research note on Thursday, June 4th. They set a “buy” rating and a $6.00 price objective for the company. One investment analyst has rated the stock with a Strong Buy rating, one has given a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $5.50.

Sera Prognostics Company Profile

Sera Prognostics, Inc is a precision medicine company focused on improving pregnancy outcomes through proteomic testing. The company’s flagship product, the PreTRM™ test, is a blood-based assay designed to assess a woman’s risk of delivering prematurely by measuring specific protein biomarkers in maternal serum. By identifying patients at elevated risk for spontaneous preterm birth, Sera Prognostics aims to enable earlier interventions and tailored care plans that can reduce the incidence of neonatal complications associated with early delivery.

Since its founding in 2014 and subsequent initial public offering in 2020, Sera Prognostics has worked closely with clinical research networks and obstetric care providers across the United States to validate the clinical performance of its PreTRM test.